Abstract
Anti-angiogenesis agents (AAs) are widely used in combination with cytotoxic agents for metastatic colorectal cancer (mCRC). Thromboembolism (TE) is an occasional adverse event specific to AAs. Once it occurs during treatment with AAs, discontinuation of AAs is recommended. There are few studies to investigate the clinical course of mCRC after TE during treatment with AAs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have